Esophagus News

Most patients who developed eosinophilic esophagitis during oral immunotherapy experienced resolution in their EoE symptoms without stopping OIT, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

Patients with food allergies and eosinophilic esophagitis have more food allergies, more allergic reactions and increased reaction severity, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

SAN ANTONIO — A high proportion of patients with eosinophilic esophagitis also had simultaneous atopic or allergic comorbid conditions, according to data presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

The elimination of animal milk alone was an effective first step in dietary therapy for patients with eosinophilic esophagitis, according to research published in The Lancet Gastroenterology & Hepatology.

A machine learning model may aid the detection and classification of tertiary lymphoid structures associated with gastrointestinal cancers based on routine tissue slides, according to research in JAMA Network Open.

The FDA has rejected Phathom Pharmaceutical’s vonoprazan new drug application for erosive esophagitis, as well as its post-approval supplement for Helicobacter pylori, due to the presence of nitrosamine impurities.

Patients with systemic sclerosis who report more severe reflux symptoms demonstrate worse interstitial lung disease outcomes despite receiving standard therapy, according to data published in Arthritis Care & Research.

Although individuals in China with low-grade intraepithelial neoplasia are at higher risk for developing esophageal squamous cell carcinoma, that risk can be reduced by more than 30% with surveillance endoscopy, according to research.

Weekly subcutaneous doses of dupilumab improved histologic outcomes and alleviated symptoms for adults and adolescents with eosinophilic esophagitis, according to a study published in The New England Journal of Medicine.

Follow-up esophagogastric junction sampling for intestinal metaplasia may not be necessary in patients after complete and successful eradication therapy for Barrett’s esophagus, researchers reported.